New book by Larry Connors Click here Improve your trading - See how
The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.
In a release, the Company noted:
The first trial, known as Encore, has enrolled its first patient. Encore is a randomized, open-label study for adult patients with Gaucher disease type 1 designed to compare Genz-112638 to Cerezyme (imiglucerase for injection). Adult patients who have previously received Cerezyme for at least three years and have reached their therapeutic goals may qualify for this trial. Genzyme expects to enroll nearly 200 patients in the Encore trial, with a treatment duration of one year.
The Engage trial is a randomized, double-blind, placebo-controlled study for patients with a confirmed diagnosis of Gaucher disease type 1. Patients with intact spleens who have not been treated in the last 12 months for Gaucher disease may qualify for this study. Genzyme expects to enroll 36 patients in the Engage trial, with a treatment duration of nine months.
Currently over 35 centers in more than 20 countries are participating in these trials. Genzyme expects that the number of recruiting centers will expand, as more sites receive regulatory approval to proceed. At the conclusion of both trials, patients will be offered the option of continuing on therapy with Genz-112638 as part of the extension phase of the program.
"We remain very enthusiastic about this potential new therapy for Gaucher disease, which could offer flexibility and choice to patients and to physicians," said Genzyme Senior Vice President Geoff McDonough, M.D. "Our studies to date for Genz-112638 suggest a potent and highly-specific therapy that was well-tolerated and that we believe could impact patients in a meaningful, positive way."
About Genz-112638
Genz-112638, a novel glucosylceramide analog given orally, is designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide. Glucosylceramide is the substance that builds up in the cells and tissues of people with Gaucher disease. In preclinical studies, the molecule has shown high potency and specificity. In February, Genzyme reported that the phase 2 clinical trial of Genz-112638 met its composite primary efficacy endpoint: a clinically meaningful response in at least two of three endpoints (improvements in spleen size, hemoglobin and platelet levels) in individual patients after the 52-week study period. The safety analysis for the phase 2 trial demonstrated that Genz-112638 was well tolerated. Related adverse events in the phase 2 study included infrequent abdominal discomfort and diarrhea, as well as transient palpitations and headache. Patients continue to be treated in the extension phase of the study and have now completed two years of treatment.
Based on its mechanism of action, which is independent of genotype, Genz-112638 is a potential therapy for all adult patients with Gaucher disease type 1. The compound was developed with James A. Shayman, M.D. from the University of Michigan.
More Information:
www.clinicaltrials.gov
((Comments on this story may be sent to health@closeupmedia.com))
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
